Introduction

BAER-101 (formerly AZD7105, see chemical structure below) is a selective partial potentiator of α2-3-containing GABA<sub>A</sub> Receptors (GABA<sub>ARs</sub>) and produces minimal sedation and dizziness. Antiepileptic effects in models of Dravet and Fragile X Syndromes have been published. BAER-101 has been administered to over 50 healthy human volunteers and found to be safe and well tolerated. To test the extent of the anti-seizure activity of BAER-101, we used the widely-used and translationally relevant Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model. This rat strain exhibits spontaneous generalized cortical seizures in the form of spike-wave discharges (SWDs) during an absence seizure in which there is behavioral arrest (Figure 1).

Structure of BAER 101

Figure 1. A representative EEG tracing showing the well-defined spike-wave discharges that occur spontaneously in the GAERS model during the generalized absence seizure period in these rats.

Study Design

14 experimentally naive, adult male GAERS (age 4 months) were obtained from Dr Antoine Depaulis (INSERM, Grenoble Institute of Neurosciences, Grenoble, France). Electrodes for spike-wave discharges (SWD) recording were implanted in all 14 rats, under general anesthesia (isoflurane; 2% in oxygen) using stereotaxic methods. There were two phases to the study. The initial phase included the following 6 conditions: Vehicle (20% HPSCD in water) PO, diazepam at 2 mg/kg IP, BAER-101 at 100 mg/kg PO, BAER-101 at 30 mg/kg PO, BAER-101 at 10 mg/kg PO, and BAER-101 at 3 mg/kg PO. Compound conditions were administered in a cross protocol, over a period, each animal received each condition, in a random order and in separate recording sessions, two animals received each condition in each recording session, and a minimal wash-out period of 7 days was allowed between each administration.

The second phase was four EEG recordings completed with the following set of compound conditions: Vehicle (20% HPSCD in water) PO, diazepam 2 mg/kg IP, and BAER-101 (0.1, 0.3, 1, and 3 mg/kg PO) administered in a cross-over protocol, following the rules: each animal received 4 different conditions from the 6 indicated above, in a random order and in separate recording sessions, animals having received the vehicle, diazepam or BAER-101 at 3 mg/kg during phase I were not assigned again to these conditions, and a minimal wash-out period of 7 days was allowed between each administration. Baseline concentrations were determined for the purpose of correlating with pharmacodynamic effects.

Statistical Methods

EEG recordings were analyzed and quantified blindly to identify SWD. Absolute data measured per 20 min periods were analyzed using a two-way ANOVA with the compound condition and the time from administration as factors. Consequently, measures were considered repeated within the time factor. When significant, ANOVA was followed by paired comparisons using a Dunnnett test, with comparisons versus the baseline period, versus vehicle, and versus diazepam. Positively data over the whole post-treatment period were analyzed using a one-way ANOVA, with the compound condition as factor. When significant, the ANOVA was followed by paired comparisons using a Dunnnett test, versus the vehicle condition.

Results

Disaccharide significantly reduced the number of SWD’s immediately after administration (Figure 2). After evaluation of results from the first 2 recordings, a near complete inhibition of SWD was seen with all doses. BAER-101 induced a dose-dependent inhibition of SWDs, and induced a significant reduction of events at all doses above 1 mg/kg PO, as compared to both the baseline and the vehicle. The effect was immediate and significant during the first measurement time-point, 10 to 90 min after administration, and remained stable over the post-treatment period.

Figure 2: Number of spike-wave discharges (SWD) per 20 min, in the vehicle condition (dark blue), diazepam at 2 mg/kg IP (light blue), and BAER-101 at 0.1 to 100 mg/kg PO (other colors). The grey arrow indicates the time of compound administration. #, ##, ###, ####: p < 0.01, 0.001 and 0.0001 as compared to vehicle.

Conclusions

Based on prior patient safety and tolerability data, coupled with the high potency and full efficacy in the GAERS model, BAER-101 is considered to be a drug suitable for advancing into human clinical trials for epilepsy.

Concentrations of BAER-101 in plasma of the rats were consistent across each EEG and blood sampling period and showed dose-dependence (Figure 4). The dose of orally administered BAER-101 was proportionally related to the concentrations of BAER-101 achieved in rat plasma, r < 0.001. The concentration of BAER-101 in plasma was significantly associated with suppression of the number of SWD. The minimal effect dose (MED) for SWD suppression was 0.3 mg/kg which generated plasma levels in rats of 3.56 mg/l; 10.1 mg/l 100 mg/kg (5x) exceeds the Ki for α2-3 containing GABA<sub>A</sub> receptors but is 23 times lower than the Ki for α5-containing GABA<sub>A</sub> receptors, demonstrating on-target engagement of BAER-101 and providing plasma levels to help guide first human dose in epileptic patients.

N
N
N
N
N
O
FO

FIGURE 3. Total time spent in SWD per 20 min, in the vehicle condition (dark blue), diazepam at 2 mg/kg IP (light blue), and BAER-101 at 0.1 to 100 mg/kg PO (other colors). The grey arrow indicates the time of compound administration. #, ##, ###, ####: p < 0.01, 0.001 and 0.0001 as compared to vehicle.

FIGURE 4. Concentrations of BAER-101 across each of the six EEG and blood sampling periods

FIGURE 5. Concentrations of BAER-101 from rat plasma as a function of dose are shown in the left panel. The relationship of BAER-101 concentration to suppression of SWD activity in the GAERS model is presented on the right. The bars are means ± S.D. The points are means.

This study was funded by Avenue Therapeutics, a pharmaceutical company developing the investigational product. For further information, contact Alexandra MacLean, MD at AMacLean@avenuetx.com

Amy S. Chappell,1, Alexis Evrard,1 Hugo Monchal,1 Corinne Rousset,1,2 and Alexandra MacLean1,2

1Avenue Therapeutics, Miami, FL, USA 2SynapCell SAS, Saint Imier, France